The Food and Drug Administration (FDA) granted priority review to the combination use of Darzalex (daratumumab), Velcade (bortezomib), melphalan and prednisone for the treatment of newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplant (ACST).
The third week in January is national Teen Cancer Awareness Week, a time to shine light on the unique medical, emotional and psychosocial needs of teens with cancer. But one organization focuses on these concerns year-round: Teen Cancer America (TCA).
While the treatment of leukemia has greatly advanced since 1946, so has the organization. In the past seven decades, LRF has raised more than $75 million for its mission of conquering not only leukemia, but all blood cancers.
A vast majority of my friends and the people that I know are in the field of nursing. Because of this, the phrase, “just a nurse” isn't one that I hear very often. That being said, I was having a conversation the other day and that sentence set my ears on fire. I was immediately taken aback by the sheer ignorance that I had been privy to.
Philippa Cheetham, MD; Sara F. Martin, MD; and Evan C. Osmundson, MD, PhD, remark on recent improvements in managing advanced lung cancer, and offer insight regarding future therapies that show promise.
Philippa Cheetham, MD; Sara F. Martin, MD; Evan C. Osmundson, MD, PhD; and Leora Horn, MD, MSc, reflect on common challenges faced while treating advanced lung cancer and discuss their considerations for creating long-term treatment plans.
Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.
Carole Brennan Miller, M.D., head of the Cancer Institute at Saint Agnes Hospital, explains what makes people with myeloproliferative neoplasms (MPNs) unique, and why she finds it interesting to work with them.